Potential Impact of Higher-Valency Pneumococcal Conjugate Vaccines Among Adults in Different Localities in Germany

J Infect Dis. 2024 Jun 14;229(6):1669-1673. doi: 10.1093/infdis/jiad538.

Abstract

Next-generation pneumococcal conjugate vaccines (PCVs) have been approved for use. The serotype distribution of pneumococcal isolates can vary between regions. To understand the potential impacts of new PCVs, we evaluated trends in invasive pneumococcal disease (IPD) among adults in Germany at a local level using Bayesian hierarchical logistic regression. There was little spatial variation in IPD cases caused by 13-valent PCV serotypes, which dropped from 60% of IPD cases in 2006 to 30% in 2018. More than half of IPD cases in 2018 were attributable to serotypes covered by new PCVs (15-valent and 20-valent PCVs), which suggests they could further reduce the burden of IPD.

Keywords: Streptococcus pneumoniae; IPD; invasive pneumococcal disease; pneumococcal disease in Germany; pneumococcal disease in adults.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Bayes Theorem
  • Female
  • Germany / epidemiology
  • Humans
  • Male
  • Middle Aged
  • Pneumococcal Infections* / epidemiology
  • Pneumococcal Infections* / immunology
  • Pneumococcal Infections* / microbiology
  • Pneumococcal Infections* / prevention & control
  • Pneumococcal Vaccines* / administration & dosage
  • Pneumococcal Vaccines* / immunology
  • Serogroup*
  • Streptococcus pneumoniae* / classification
  • Streptococcus pneumoniae* / immunology
  • Vaccines, Conjugate* / administration & dosage
  • Vaccines, Conjugate* / immunology
  • Young Adult

Substances

  • Pneumococcal Vaccines
  • Vaccines, Conjugate
  • 13-valent pneumococcal vaccine